ASTCT Pharmacy SIG Online Journal Club - November 2021

Presenters & Articles

Lindsey Catlin, PharmD
PGY2 Oncology Resident
St Luke's Health System
Autologous Transplant versus Chimeric Antigen Receptor T-cell Therapy for Relapsed DLBCL in Partial Remission

Jack Malespini, PharmD
PGY2 Oncology Pharmacy Resident
Massachusetts General Hospital
jmalespini@mgh.harvard.edu 
Post-transplant Cyclophosphamide Versus Thymoglobulin in HLA Mismatched Unrelated Donor Transplant for Acute Myelogenous Leukemia and Myelodysplastic Syndrome

Session Learning Objectives:

Upon completion of the activity, participants should be able to:

- Discuss recent BMT pharmacy studies and their applications to current practice.
- Evaluate the role of autologous transplant versus treatment with chimeric antigen receptor t-cell therapy in patients with relapsed DLBCL in partial remission.
- Compare and contrast the utility of post-transplant cyclophosphamide (PTcy) versus thymoglobulin for graft versus host disease (GVHD) prophylaxis in mismatched unrelated donor (MMUD) transplantation.

This activity is jointly provided by The France Foundation and ASTCT. The France Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education and will award 1.0 CEU to pharmacists who complete the activity, complete the registration and evaluation forms, and successfully pass a post-test (>75%).

Full CE information, including presenter disclosures and accreditation information, can be found in the Handouts tab or directly downloaded by clicking here.